| 8.775 0.005 (0.06%) | 05-23 10:42 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.66  |
1-year : | 14.92 |
| Resists | First : | 10.84 |
Second : | 12.77 |
| Pivot price | 9.99 |
|||
| Supports | First : | 7.7 |
Second : | 6.41 |
| MAs | MA(5) : | 9.43 |
MA(20) : | 9.73 |
| MA(100) : | 6.07 |
MA(250) : | 3.13 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 16.9 |
D(3) : | 25.7 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 12.77 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DBVT ] has closed above bottom band by 12.7%. Bollinger Bands are 65% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.22 - 9.31 | 9.31 - 9.37 |
| Low: | 8.41 - 8.52 | 8.52 - 8.58 |
| Close: | 8.64 - 8.82 | 8.82 - 8.94 |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Fri, 23 May 2025
Buy Rating for DBV Technologies Driven by Promising Viaskin Peanut Potential and Strong Market Opportunity - TipRanks
Wed, 21 May 2025
Are Medical Stocks Lagging DBV Technologies (DBVT) This Year? - Yahoo Finance
Fri, 16 May 2025
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
Thu, 15 May 2025
DBV Technologies Sets Critical Shareholder Meeting: Key Documents Now Available - Stock Titan
Tue, 13 May 2025
DBV Technologies: A Great Time To Sell (NASDAQ:DBVT) - Seeking Alpha
Mon, 05 May 2025
DBV Technologies CEO Set for Key Presentation: How to Watch Live Fireside Chat at JMP Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 7.379e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 562 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 534.9 % |
| Return on Equity (ttm) | -73 % |
| Qtrly Rev. Growth | 3.5e+006 % |
| Gross Profit (p.s.) | -193.75 |
| Sales Per Share | -826.96 |
| EBITDA (p.s.) | 1.45833e+007 |
| Qtrly Earnings Growth | -5.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 69.41 |
| Dividend | 0 |
| Forward Dividend | 160140 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|